Author:
Goldwirt L.,Chami I.,Feugeas J.-P.,Pages C.,Brunet-Possenti F.,Allayous C.,Baroudjian B.,Madelaine I.,Sauvageon H.,Mourah S.,Lebbé C.
Reference4 articles.
1. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance;Funck-Brentano;Ann Oncol,2015
2. Public assessment report on Zelboraf®, EMA/200986/2012;EMEA,2012
3. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study;McArthur;Lancet Oncol,2014
4. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma;Kramkimel;Target Oncol,2015
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献